Array
(
    [results] => Array
        (
            [0] => Array
                (
                    [ArticleID] => 209261
                    [Title] => NSAIDs for one year failed to show  Alzheimer’s disease
                    [Summary] => Neither the selective cyclooxygenase-2inhibitor rofecoxib nor the nonselective NSAID naproxen slowed the rate of cognitive or functional decline in a one-year, placebo-controlled study of patients with Alzheimer’s disease, it was reported at the Eighth International Conference on Alzheimer’s disease and Related Disorders. 


                    [DatePublished] => 2003-06-08 00:00:00
                    [ColumnID] => 136231
                    [Focus] => 0
                    [AuthorID] => 1805110
                    [AuthorName] => Charles C. Chante MD
                    [SectionName] => Opinion
                    [SectionUrl] => opinion
                    [URL] => 
                )

        )

)

DISEASE ASSESSMENT SCALE

Array
(
    [results] => Array
        (
            [0] => Array
                (
                    [ArticleID] => 209261
                    [Title] => NSAIDs for one year failed to show  Alzheimer’s disease
                    [Summary] => Neither the selective cyclooxygenase-2inhibitor rofecoxib nor the nonselective NSAID naproxen slowed the rate of cognitive or functional decline in a one-year, placebo-controlled study of patients with Alzheimer’s disease, it was reported at the Eighth International Conference on Alzheimer’s disease and Related Disorders. 


                    [DatePublished] => 2003-06-08 00:00:00
                    [ColumnID] => 136231
                    [Focus] => 0
                    [AuthorID] => 1805110
                    [AuthorName] => Charles C. Chante MD
                    [SectionName] => Opinion
                    [SectionUrl] => opinion
                    [URL] => 
                )

        )

)

abtest

NSAIDs for one year failed to show Alzheimer’s disease

By YOUR DOSE OF MEDICINE | By Charles C. Chante MD | June 8, 2003 - 12:00am

Neither the selective cyclooxygenase-2inhibitor rofecoxib nor the nonselective NSAID naproxen slowed the rate of cognitive or functional decline in a one-year, placebo-controlled study of patients with Alzheimer’s...

Opinion